Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Blockbuster Drugs: Endangered Species?
Our list of top-selling drugs of the 21st century shows how much money those drugs made between 2000 and 2011; the total amounts for all of them are in the billions. However, given the advent of personalized medicine and the increasing number of biosimilars entering the market, will pharmaceutical giants be able to maintain that level of success, or does our list contain the last of the blockbusters?